Stephens Inc Alaunos Therapeutics, Inc. Transaction History

Stephens Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.46 - $0.81 $4,600 - $8,100	-10,000 Reduced 39.74%	15,162 $9,000
Q3 2021 Oct 27, 2021	BUY	$1.44 - $2.73 $7,200 - $13,650	5,000 Added 24.8%	25,162 $46,000
Q1 2021 May 14, 2021	BUY	$2.82 - $5.6 $56,856 - $112,907	20,162 New	20,162 $73,000
Q4 2020 Feb 10, 2021	SELL	$2.09 - $3.09 $227,143 - $335,824	-108,681 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.39 - $3.43 $148,904 - $213,699	62,303 Added 134.34%	108,681 $274,000
Q1 2020 May 14, 2020	BUY	$1.9 - $4.98 $8,572 - $22,469	4,512 Added 10.78%	46,378 $114,000
Q4 2019 Feb 14, 2020	BUY	$3.95 - $5.35 $38,860 - $52,633	9,838 Added 30.72%	41,866 $198,000
Q3 2019 Oct 18, 2019	SELL	$4.13 - $6.94 $5,575 - $9,369	-1,350 Reduced 4.04%	32,028 $137,000
Q1 2019 May 03, 2019	BUY	$2.0 - $4.4 $4,000 - $8,800	2,000 Added 6.37%	33,378 $129,000
Q3 2018 Nov 14, 2018	BUY	$2.26 - $3.27 $70,914 - $102,606	31,378 New	31,378 $100,000
Q3 2017 Nov 08, 2017	SELL	$4.99 - $6.57 $195,148 - $256,939	-39,108 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	39,108	39,108 $243,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

Stay updated on Stephens Inc with notifications on news.